This week, there’s a significant development in the ongoing Valsartan multi-district litigation (MDL). The judge overseeing the case has selected five plaintiffs’ lawsuits to proceed to the next round of bellwether trials. These trials play a crucial role in advancing the litigation process. When bellwether trials result in favorable verdicts for plaintiffs, it often prompts [...]
On December 16, 2024, the federal judge overseeing the Valsartan litigation confirmed the selection of five cases for the second set of bellwether trials. These trials are part of the multidistrict litigation (MDL) against the manufacturers of Valsartan, specifically addressing the harmful effects of NDMA contamination in the medication. MDL 2875 includes individuals who were [...]
After the postponement of the first lawsuit selected for a bellwether trial, a new case has been scheduled to kick off the trials. The first trial will now involve a lawsuit filed by an Alabama man who developed liver cancer after taking Valsartan. This case is seen as a stronger choice, as it will provide [...]
As the first bellwether trial in the Valsartan multi-district litigation (MDL) draws near, we are seeing an increase in interest surrounding the case. This is a common development, and we anticipate continued inquiries and new Valsartan claims for the foreseeable future. If you believe you may have a claim, now is the time to act. [...]
